Preoperative Treatment With Cetuximab and/or IMC-A12: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Preoperative Treatment With Cetuximab and/or IMC-A12 (NCT00957853), a randomized phase 2 study. The primary outcome is AKT Modulation.

2. Clinical Question

3. Trial Design

NCT00957853, titled “Preoperative Treatment With Cetuximab and/or IMC-A12,” was a randomized Phase 2 study sponsored by M.D. Anderson Cancer Center. The registry records a parallel-group design with no masking. The study is marked completed, with enrollment of 16. Its recorded start date is 2011-10-17, and its primary completion date is 2018-08-15.

The three groups received cetuximab, IMC-A12, or the combination before surgery. The cetuximab-only regimen was 400 mg/m2 intravenously over 120 minutes on week 1, followed by 250 mg/m2 intravenously over 60 minutes on weeks 2 and 3. The IMC-A12-only regimen was 6 mg/kg/week intravenously over 1 hour on weeks 1, 2, and 3. The combination group received both regimens. Surgical tumor resection was also listed as an intervention.

The study’s stated purpose was to assess whether these preoperative treatments were associated with changes in biomarkers in blood and/or tissue. The registry also says safety would be studied. The primary outcome focused on phospho-Akt modulation, defined as the difference in immunohistochemistry score between the surgical specimen and baseline biopsy. The planned timing was a baseline biopsy and surgery, with surgery intended to occur within 10 days of the last treatment.

Although the registry describes randomization and the planned comparisons, it does not report the randomization method, allocation concealment, or a protocol-level explanation of the group assignment process. Details of the sample-size justification and any interim analyses are not reported in the registry record. The study ended before primary outcome data could be collected, limiting what can be learned from the planned biomarker comparison.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: A total of 16 patients were enrolled in the study; however only 15 patients were started on the trial since 1 subject withdrew consent for the study.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Due to early termination of the study, data could not be collected for this outcome.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as AKT Modulation, measured over Biopsy at baseline and surgery (surgery should be within 10 days of last treatment).

The primary endpoint, called AKT Modulation, was intended to measure change in phospho-Akt staining from the baseline biopsy to the surgical specimen. The registry describes an immunohistochemistry scoring system combining staining intensity with the extension of staining. Intensity was graded as undetectable (0), weak (1), medium (2), or strong (3). Extension was recorded as the percentage of positive cells per high power field at x20 magnification. The final score was specified to range from 0 to 300.

The endpoint was defined as the difference between the surgical-specimen score and the baseline-biopsy score. Comparing a tissue measure before and after preoperative treatment was intended to assess biomarker modulation, rather than directly measure a clinical outcome such as survival. The registry also proposed comparisons of biomarker modulation between any two of the three treatment arms using the Wilcoxon rank sum test. Associations between biomarkers and molecular response or toxicity were described as exploratory.

The planned assessment required paired tissue collection at baseline and surgery. The registry states that, because the study ended early, data could not be collected for this outcome. It therefore does not report endpoint values, changes, or between-arm estimates. The endpoint’s scoring rules and intended use are described, but they cannot establish whether phospho-Akt changed in the enrolled participants.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What was the planned comparison?

The study had three randomized parallel groups: cetuximab, IMC-A12, and the combination. The primary outcome description planned comparisons between any two of these arms. For each participant, the intended biomarker measure was a difference between the surgical specimen’s immunohistochemistry score and the baseline biopsy score. This makes the outcome a change score, with positive or negative direction depending on the relationship between the two specimen scores. The registry defines the subtraction order as surgical specimen minus baseline biopsy.

The record names the Wilcoxon rank sum test for comparisons of biomarker modulation between arms. General explanation: this is a rank-based method for comparing the distributions of observations in two independent groups. It can be useful when an analysis does not rely on a normal-distribution model for the raw outcome, though the interpretation depends on the distributions and the estimand of interest. The registry does not report the actual data, test statistic, p-value, or effect estimate, so no conclusion from this test is available.

What does the scoring system represent?

The immunohistochemistry score combines staining intensity with the extension of staining. Intensity categories were undetectable (0), weak (1), medium (2), and strong (3); extension was the percentage of positive cells per high power field at x20 magnification. The stated final score range is 0 to 300. General explanation: converting a staining pattern into a score can make tissue measurements easier to compare, but the score is an operational measure of staining, not a direct measure of a clinical outcome. The registry does not report how scoring reliability was assessed, whether scorers were blinded to treatment, or how disagreements were resolved.

How should the significance level be read?

The planned analysis specified Type I error alpha=0.05 with a two-sided test. General explanation: a significance level describes a threshold used in a testing procedure under its assumptions; it is not the probability that a particular result is true and does not measure the size or clinical importance of an effect. A two-sided test allows for differences in either direction. Since the primary outcome data were not collected, the stated threshold does not correspond to a reported test result.

Why does the three-arm structure matter?

With three arms, several pairwise comparisons could be of interest. The registry says comparisons would be made between any two treatment arms, but does not report whether a multiplicity adjustment was planned. General explanation: when several hypotheses are tested, the chance of at least one false positive across the family of tests can differ from the chance attached to one test. Adjustment choices and the family of comparisons should be specified in advance to support interpretation. Here, no completed biomarker comparisons are posted, and the statistical handling of multiplicity is not reported in the registry record.

What does the planning information mean?

The record describes sample-size planning illustrations based on the observed effect, with a two-sided significance level of 0.05, equal allocation between two arms, a normal approximation, and an effect to detect defined as a stated fraction of the observed effect. General explanation: such calculations describe how many participants per arm might be needed under the stated assumptions; they do not describe the number who were actually analyzed, and they are not observed power. The registry does not report its own sample-size justification. Because the primary endpoint data were not collected and the record contains no observed effect estimate for that endpoint, those planning assumptions cannot be read as evidence of a biomarker effect.

The record lists no completed analyses. It also does not report the analysis population, a method for handling missing primary outcome measurements, or details of the statistical model beyond the named rank sum test and stated significance level. These omissions matter because analysis choices can affect how a result is estimated and interpreted. In this trial, however, the more fundamental issue is that the planned primary outcome was unavailable for analysis.

10. Multiplicity, Missing Data and Analysis Populations

The primary outcome description proposes comparing biomarker modulation between any two of the three randomized arms. That is a set of potential pairwise comparisons, but the registry record does not report a multiplicity-control procedure or identify a hierarchy among the comparisons. General explanation: when several comparisons are considered together, an analysis plan commonly needs to state whether the goal is to control the error rate across the full family or to treat tests as exploratory. Without that information, a reported isolated p-value could be difficult to interpret in context. No completed primary outcome comparisons or p-values are reported.

Missingness is especially consequential because the registry states that data could not be collected for the primary outcome due to early termination. It does not describe the number of participants with baseline biopsies, the number with surgical specimens, or a method for handling incomplete paired measurements. It also does not report an analysis population for AKT modulation. These details are not reported in the registry record, so the extent and pattern of missing primary endpoint data cannot be characterized beyond the statement that the outcome data could not be collected.

The registry lists objective response as a secondary outcome but does not provide a result or analysis population for it. It does not report how missing secondary outcome data were handled. The analysis populations for the adverse-event counts are described through the numbers at risk in each group, but no broader population definitions are given. The record also does not report interim analyses. These absences prevent a fuller assessment of how planned analyses, missing observations, and multiple comparisons were addressed.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent non-serious adverse event terms

The registry reports serious adverse events separately from other adverse events. No participants are listed as affected by a serious adverse event in the cetuximab group, with 4 at risk; the IMC-A12 group, with 6 at risk; or the combination group, with 5 at risk. It reports other adverse events affecting 2 participants in the cetuximab group, 2 in the IMC-A12 group, and 4 in the combination group. Deaths are reported as zero in each group.

These are counts, not descriptions of individual events. The registry record does not report the serious adverse-event terms, and it does not provide details in these figures about the kinds of other adverse events, their severity, timing, duration, or relationship to treatment. The numbers at risk also do not explain why the group counts differ from the overall enrollment of 16. The figures therefore describe what was recorded in these safety categories, but they are not enough to characterize the full safety profile or make a reliable comparison between treatment groups.

12. What the Result Does, and Does Not, Mean

This trial’s registry record documents an intended randomized comparison of three preoperative approaches and a specific plan to assess phospho-Akt modulation in tissue. It also records adverse-event counts for the three treatment groups. The principal finding about the primary endpoint is not a measured treatment effect: the registry says the data could not be collected because of early termination.

That distinction matters. A missing outcome is not evidence that treatment groups had the same biomarker change, nor is it evidence that they differed. The record contains no primary endpoint estimate, confidence interval, or completed test to show the direction, magnitude, or precision of any difference. The stated Wilcoxon rank sum test and significance level describe the planned method, not a result.

The same caution applies to objective response. It is named as a secondary outcome, but its result is not reported in the registry record. The safety counts indicate no reported serious adverse events or deaths in the listed groups and report counts for other adverse events. They do not, on their own, establish comparative safety, explain event characteristics, or establish whether events were caused by study treatment.

As a result, the record supports a description of the trial’s design, planned biomarker measurement, and posted safety counts, but it does not answer the primary biological question. It cannot be used to claim that a treatment changed phospho-Akt, that the three approaches were equivalent, or that any difference was absent. The limits arise from missing primary endpoint data and the lack of posted outcome analyses, not from a demonstrated null result.

13. Why This Trial Matters Statistically

This study is statistically informative as an example of the difference between a prespecified outcome and an observed result. The registry defines a tissue-based change score, specifies its timing and scoring system, and names a planned test for comparisons between treatment arms. Those details show how a biomarker question can be translated into a measurable endpoint. But a well-described endpoint does not become an empirical finding unless the measurements are collected and analyzed.

The randomized, parallel, three-arm design was intended to compare distinct preoperative treatment approaches. In principle, comparing change from baseline can help distinguish biomarker levels before treatment from levels in the surgical specimen. General explanation: paired measurements can account for the fact that participants may begin with different baseline values, while between-arm comparisons address whether observed changes vary across assigned groups. These benefits depend on having usable measurements at both time points and a prespecified, adequately supported analysis.

Here, early termination meant the primary outcome could not be collected. That makes completeness of outcome ascertainment central to interpretation: no statistical method can recover the planned biomarker comparison when the relevant outcome data are unavailable. The registry also leaves the sample-size justification, missing-data methods, and multiplicity plan unreported. These are important elements for understanding the intended strength and scope of inference, but they cannot substitute for the missing observations.

The safety entries remain a separate kind of information. They offer counts for serious and other adverse events, but not the clinical detail needed to interpret event patterns. Statistically, the trial therefore illustrates why design, measurement, data collection, and analysis must all be considered together. The planned methods describe the intended evidence; the results that can be interpreted depend on what was actually collected and posted.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The clearest trial-specific limitation is that the primary biomarker outcome was unavailable. The registry attributes this to early termination and reports that data could not be collected. It gives no baseline or surgical specimen scores, no change estimates, and no completed between-arm analysis. This prevents assessment of the endpoint’s direction, magnitude, variability, or precision.

The registry reports enrollment of 16, while the safety counts list 4, 6, and 5 participants at risk across the three treatment groups. It does not explain the relationship between those figures, provide a participant flow account, or identify the analysis populations. The primary outcome description also does not report how many participants had each required specimen or how missing paired measurements would have been handled.

Several design and analysis details are not reported in the registry record: the randomization procedure, allocation concealment, the study’s own sample-size justification, interim analyses, multiplicity handling, and details of the scoring process such as assessor blinding or reliability. The planned primary analysis is described as a Wilcoxon rank sum test with a two-sided Type I error of alpha=0.05, but no analysis results are posted.

The secondary objective-response outcome is listed without a result. Safety information is limited to counts in broad categories; event terms for serious adverse events are not listed, and the record does not provide event-level descriptions. These reporting limits mean that the available record cannot support a complete efficacy, biomarker, or comparative safety assessment.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Preoperative Treatment With Cetuximab and/or IMC-A12 — NCT00957853.
• Registry record last updated 2020-03-19; status last verified 2020-03.
• Results first posted 2020-03-19.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT00957853 was a randomized, unmasked, parallel Phase 2 study of preoperative cetuximab, IMC-A12, or both for head and neck squamous cell carcinoma. It was sponsored by M.D. Anderson Cancer Center, recorded enrollment of 16, and is marked completed. The registry lists a start date of 2011-10-17 and a primary completion date of 2018-08-15.

The primary outcome was planned to measure change in phospho-Akt immunohistochemistry score between baseline biopsy and surgical specimen. The registry states that early termination prevented collection of this outcome. Objective response is listed as a secondary outcome, but its result is not reported in the registry record. Safety entries report zero serious adverse events and zero deaths in each group, with other adverse events affecting 2, 2, and 4 participants in the cetuximab, IMC-A12, and combination groups, respectively.

The record describes a planned biomarker analysis but does not report its results. It also does not report the study’s sample-size justification, interim analyses, missing-data methods, or multiplicity procedure.